Prosecution Insights
Prosecution Insights
5 pending office actions • 1 client • 5 examiners • 5 art units • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 2 (40%) |
| Double-patenting only | 1 (20%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEIN, LEAH ELIZABETH | 1 | 100.0% | +0.0% |
| HOLTZMAN, KATHERINE ANN | 1 | 64.5% | +57.9% |
| DUFFY, BRADLEY | 1 | 54.4% | +45.4% |
| LANDSMAN, ROBERT S | 1 | 81.3% | +12.9% |
| HOWARD, ZACHARY C | 1 | 63.9% | +38.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263439 | NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | STEIN, LEAH ELIZABETH | 85d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18255049 | CD19-TARGETING HUMANIZED ANTIBODY AND USE THEREOF | DUFFY, BRADLEY | 67d overdue |
| 18034167 | BCMA-TARGETING SINGLE-DOMAIN ANTIBODY AND USE THEREOF | HOWARD, ZACHARY C | 30d overdue |
| 18260905 | ROR1-TARGETING ANTIBODY AND USE THEREOF | HOLTZMAN, KATHERINE ANN | 23d overdue |
| 18034177 | CHIMERIC ANTIGEN RECEPTOR TARGETING CD7 AND USE THEREOF | LANDSMAN, ROBERT S | 28d |
| Client (Assignee) | Pending OAs |
|---|---|
| Bioheng Therapeutics | 5 |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1646 | 1 |
| 1643 | 1 |
| 1647 | 1 |
| 1674 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18263439 | NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | BIOHENG THERAPEUTICS LIMITED | STEIN, LEAH ELIZABETH | 1641 | DP | Non-Final OA | 85d | Pending | Jul 28, 2023 |
| 18260905 | ROR1-TARGETING ANTIBODY AND USE THEREOF | BIOHENG THERAPEUTICS LIMITED | HOLTZMAN, KATHERINE ANN | 1646 | §112 | Non-Final OA | 23d overdue | Pending | Jul 10, 2023 |
| 18255049 | CD19-TARGETING HUMANIZED ANTIBODY AND USE THEREOF | BIOHENG THERAPEUTICS LIMITED | DUFFY, BRADLEY | 1643 | §103 | Non-Final OA | 67d overdue | Pending | May 30, 2023 |
| 18034177 | CHIMERIC ANTIGEN RECEPTOR TARGETING CD7 AND USE THEREOF | BIOHENG THERAPEUTICS LIMITED | LANDSMAN, ROBERT S | 1647 | Other | Non-Final OA | 28d | Pending | Apr 27, 2023 |
| 18034167 | BCMA-TARGETING SINGLE-DOMAIN ANTIBODY AND USE THEREOF | BIOHENG THERAPEUTICS LIMITED | HOWARD, ZACHARY C | 1674 | §112 | Non-Final OA | 30d overdue | Pending | Apr 27, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial